Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.
Keyphrases
- multiple myeloma
- high intensity
- acute lymphoblastic leukemia
- acute myeloid leukemia
- emergency department
- transcranial direct current stimulation
- diffuse large b cell lymphoma
- intensive care unit
- respiratory failure
- working memory
- acute respiratory distress syndrome
- mechanical ventilation
- aortic dissection
- adverse drug
- hodgkin lymphoma